Treatment Extends Brain Tumor Survival Rate?
Posted on: Tuesday, 10 March 2009, 14:22 CDT
The final results of a clinical trial show adding chemotherapy to radiotherapy treatment for brain tumors can extend a patient's survival for up to five years.
Researchers focused their study on the most common and aggressive brain tumor, glioblastoma. For over 30 years, post-operative radiotherapy was the standard treatment, but only offered modest survival benefits -- about nine months. In the clinical trial, scientists gave patients the chemotherapy drug temozolomide in combination with radiotherapy.
Findings showed at three years, 16 percent of patients receiving the combination treatment were alive compared with only 4 percent of patients who were receiving radiotherapy. At five years, that comparison was nearly 10 percent survival versus a 2 percent survival rate.
The authors noted no difference in the pattern of recurrence between patients who were treated with radiotherapy alone or with the addition of chemotherapy. Researchers caution that while the combined therapy may be effective in reducing tumor bulk and aggressiveness, it is unlikely to lead to a cure.
SOURCE: The Lancet Oncology online edition, March 2009
Source: Ivanhoe
Related Articles
- New Test to Predict How Breast Cancer Patients Respond to Chemotherapy
- Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients With Treatment-Resistant Forms of Advanced Leukemias
- Study Showed Treatment With COPAXONE(R) is Associated With Significantly Fewer Days Missed From Work in Multiple Sclerosis Patients; Non-Treatment and Treatment With Avonex(R) or Betaseron(R) Had No Significant Impact on Days Missed
- Women Surviving Cardiovascular Disease Treatment in Nation's Hospitals at Higher Rates, Says HealthGrades Study
- Study Published in Journal of Clinical Psychiatry Shows Long-Term Treatment- As-Usual Is Ineffective for Patients With Treatment-Resistant Depression
- Two-Year Data Showing Decreases in Suicidality in Patients With Treatment- Resistant Depression Treated With VNS Therapy Presented at Annual American Psychiatric Association Meeting
- Savient's Puricase(R) (PEG-Uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients With Treatment-Resistant Gout
- Comparison of Different Methods for Delineation of ^Sup 18^F-FDG PET- Positive Tissue for Target Volume Definition in Radiotherapy of Patients With Non-Small Cell Lung Cancer
- Patients With Treatment-Resistant Schizophrenia Get Good News Today at American Psychiatric Association Meeting in Atlanta
- A Prospective Study of Concurrent Cyclophosphamide/Methotrexate/5- Fluorouracil and Reduced-Dose Radiotherapy in Patients With Early- Stage Breast Carcinoma
 |
 |
User Comments (0)
RSS Feeds